HUTCHMED (NASDAQ:HCM) Shares Gap Up – What’s Next?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)’s share price gapped up before the market opened on Monday . The stock had previously closed at $13.81, but opened at $14.40. HUTCHMED shares last traded at $14.2460, with a volume of 15,630 shares trading hands.

Analysts Set New Price Targets

HCM has been the topic of a number of research reports. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Finally, Bank of America decreased their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $16.88.

HUTCHMED Price Performance

The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $14.64 and its 200-day moving average price is $14.80.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings data on Friday, March 6th. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The company had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. Research analysts forecast that HUTCHMED will post 0.16 EPS for the current year.

Hedge Funds Weigh In On HUTCHMED

Hedge funds have recently bought and sold shares of the business. Jane Street Group LLC increased its stake in HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after purchasing an additional 124,771 shares during the period. UBS Group AG boosted its stake in shares of HUTCHMED by 112.8% during the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after purchasing an additional 72,614 shares during the period. Amundi grew its holdings in shares of HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after purchasing an additional 65,898 shares during the last quarter. M&G PLC increased its stake in HUTCHMED by 26.7% in the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after buying an additional 54,601 shares during the period. Finally, Tema Etfs LLC purchased a new position in HUTCHMED in the 2nd quarter worth about $641,000. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.